Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013543 · ClinicalTrials.gov registry record · Phase 2
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
A Phase 2 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
NCT03013543 is a Phase 2 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 213 participants.
The verdict
NCT03013543, a Phase 2 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.
Interventions
- DRUG Setmelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03013543
The ClinicalTrials.gov registry entry for NCT03013543 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Setmelanotide is the first listed.
NCT03013543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03013543 about?
NCT03013543 is a clinical study titled "Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity". The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.
What is the current status of trial NCT03013543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2017-02-10. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT03013543?
The interventions under investigation include: Setmelanotide (DRUG).
Who is sponsoring clinical trial NCT03013543?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.